Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial

Rhea-AI Summary

Science 37 Holdings, a leader in patient access to clinical trials, announced that it exceeded enrollment goals in a Phase 2 clinical trial for EP547, a treatment for Cholestatic Pruritus in Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis. Over a 20-month period, Science 37 enrolled 21% of participants, achieving an enrollment rate of 1 patient per month, significantly faster than the 0.1 patients per month at traditional sites. This was made possible through their proprietary Metasite™ and Patient Recruitment solutions, which broaden the pool of qualified participants beyond local trial site areas.

Positive

• Science 37 surpassed its contracted enrollment goals, enrolling 21% of participants.
• Enrollment rate of 1 patient per month, compared to 0.1 at traditional sites.
• Utilization of Metasite™ and Patient Recruitment solutions increased efficiency.
• Broadened the pool of qualified participants beyond local trial site areas.
• Significantly faster enrollment speed, 11x that of traditional research sites.

Negative

• Study protocol required a highly specific patient population, potentially limiting broader application.
• The trial’s progress heavily reliant on Science 37’s virtual solutions, which could pose risks if technology fails.

Clinical Research Analyst

Science 37's achievement in surpassing enrollment goals by leveraging virtual recruitment solutions is a significant development in clinical research. By enrolling 21% of study participants in a rare disease trial, they have demonstrated their ability to overcome the geographical limitations of traditional recruitment methods. The accelerated pace, enrolling patients at 11 times the traditional rate, indicates a potentially substantial reduction in trial timelines.

For investors, this showcases Science 37’s competitive edge in the clinical trial space. The ability to reach a broader patient pool for rare disease research is particularly valuable, as these trials often face challenges due to the limited number of eligible participants. This could mean faster time-to-market for new therapies, which is a critical factor for pharmaceutical companies.

Moreover, the success with the EP547 trial could lead to increased demand for Science 37’s services from other clinical-stage companies. This could translate into revenue growth and a stronger market position.

In summary, the enhanced recruitment capabilities and the resulting reduction in trial durations could attract more clients to Science 37, potentially boosting their financial outlook.

Market Research Analyst

The announcement from Science 37 highlights a significant shift in clinical trial methodologies. Traditionally, patient recruitment has been a pain point due to geographic constraints and lengthy timelines. By leveraging their virtual Metasite™ and patient recruitment solutions, Science 37 addresses these issues head-on, offering a scalable solution.

For stakeholders, this is a pivotal differentiator. The ability to recruit at an 11x faster rate than traditional sites not only positions Science 37 as a leader in the field but also enhances the attractiveness of their services to potential clients. This innovation could lead to a paradigm shift in how clinical trials are conducted, especially in rare disease research where patient availability is a critical challenge.

Investors should note the broader market implications: a successful deployment in this Phase 2 trial can serve as a proof-of-concept for other trials, potentially leading to widespread adoption of virtual recruitment methods. This could open new revenue streams and partnerships, bolstering the company’s market position.

In essence, this achievement could signify a broader market trend towards virtualization in clinical trials, benefiting Science 37 considerably.

Science 37 Enrolls 21% of Study Participants at 11x the Speed of Traditional Research Sites Through its Virtual Site and Patient Recruitment Solutions

RESEARCH TRIANGLE PARK, N.C., June 12, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc., a leader in enhancing patient access to clinical trials, announced the final enrollment figures from its 20-month engagement with a clinical-stage drug development company advancing novel small molecule therapeutics for systemic neuro-immune disorders.

Science 37 augmented the recruitment and enrollment activities taking place at study sites nationwide for this ongoing Phase 2 trial evaluating the effects of EP547 in patients with Cholestatic Pruritus due to Primary Biliary Cholangitis (PBC) or Primary Sclerosing Cholangitis. The study protocol mandated a highly specific patient population, requiring participants to undergo evaluation against rigorous inclusion and exclusion criteria.

Leveraging its proprietary Metasite™ and Patient Recruitment solutions, Science 37 contributed 21% of all randomized study participants between September 2022 and April 2024. Science 37 surpassed its contracted enrollment goal, achieving an average enrollment rate of 1 patient per month, compared to the 0.1 patients per month rate at each of the 51 participating traditional brick-and-mortar sites.

“Traditional recruitment methods are geographically limited, whereas Science 37 can recruit and enroll patients located anywhere, not just within a certain travel radius of a trial site. This significantly broadens the pool of qualified participants, which is vital for rare disease research,” explained Erica Prowisor, SVP of Patient and Provider Networks at Science 37.

Science 37’s Patient Recruitment is available on a standalone basis to clinical research sponsors and CROs looking to enhance their patient enrollment efforts, or in combination with Science 37’s industry-leading flagship Virtual Site, the Metasite™, as part of an accelerated research offering. For more information, please visit www.science37.com.

About Science 37

Science 37’s mission is to accelerate clinical research by enabling universal trial access for patients. Through our solutions; the Metasite™ and Patient Recruitment, we accelerate enrollment by expanding the reach of clinical trials to patients beyond the traditional site and rigorously qualifying patients prior to referring them to a traditional site. Our solutions are powered by a proprietary technology stack with in-house medical and operational experts that enhance quality through standardized workflows and best-in-class study orchestration. To learn more, visit www.science37.com, or email science37@science37.com.

To view studies that Science 37 is actively recruiting for, please visit https://studies.science37.com/current-studies.

Media Inquiries

Science 37
PR@science37.com

FAQ

What recent achievement did Science 37 announce in their Phase 2 clinical trial?

Science 37 announced that they surpassed enrollment goals, enrolling 21% of participants in a Phase 2 clinical trial for EP547.

How does Science 37's enrollment rate compare to traditional sites?

Science 37 achieved an enrollment rate of 1 patient per month, compared to 0.1 patients per month at traditional research sites.

What is EP547 being tested for in Science 37's Phase 2 trial?

EP547 is being tested for treating Cholestatic Pruritus in patients with Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis.

What technology did Science 37 use to surpass enrollment goals?

Science 37 used its proprietary Metasite™ and Patient Recruitment solutions to surpass enrollment goals.

What is the advantage of Science 37's recruitment methods?

Science 37's methods are not geographically , allowing recruitment from a broader pool of qualified participants.